

MAKING EVIDENCE RELEVANT



December 2013

[French version](#)

About this bulletin

This bulletin is published by Health Quality Ontario ([HQO](#)) to update you on the work of its Ontario Health Technology Advisory Committee ([OHTAC](#)), Evidence Development and Standards ([EDS](#)) branch and research collaborators.

Questions and comments

EDSinfo@hqontario.ca

OHTACinfo@hqontario.ca.

To subscribe

Subscriptions@hqontario.ca.

Posted for Public Comment:

[Optical Coherence Tomography Monitoring Strategies for A-VEGF Age-Related Macular Degeneration](#)

Age-related macular degeneration (AMD) is a major retinal disease and the leading cause of irreversible vision loss and blindness in older adults. The emergence of new drugs, targeting -vascular endothelial growth factors (A-VEGF), has dramatically altered the treatment of AMD. Optical coherence tomography (OCT) has emerged as a key technology for monitoring treatment strategies for AMD and other retinal disorders. HQO conducted an evidence-based analysis to determine the appropriate monitoring interval with OCT for patients with AMD undergoing intraocular injections.

Based on the evidence, OHTAC recommends that access to OCT be provided monthly as the basis for guiding treatment decisions during the monitoring and ongoing drug-treatment phase for AMD. The draft research and recommendations are posted for public comment for 21 days.

[Click here](#) to find out more.

